Overweight
Conditions
Interventions
This is a randomized, controlled and parallel clinical study. Control group: twenty-seven men and women who are overweight (BMI = 27 kg/m²), high waist circumference (= 80 cm for women
= 90 cm for men) and excess body fat (> 30% for women and > 20% for men) associated with at least one other component of the Metabolic Syndrome: triglycerides =150 mg/dL
blood pressure = 130/85 mmHg) or fasting blood glucose =100 mg/dL or obesity (BMI = 30 kg/m²) regardless of the presence of other components of the Metabolic Syndrome will receive a calorie-restricted
Sponsors
Universidade Federal de Viçosa
Embrapa Agroindústria Tropical
Eligibility
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: Men and women between 20 and 55 years old; Excess weight (= 27 kg/m²), high waist circumference (= 80 cm for women; = 90 cm for men) and excess body fat (> 30% for women and > 20% for men) associated with another component of the Metabolic Syndrome: triglycerides =150 mg/dL; blood pressure = 130/85 mmHg) or fasting glucose =100 mg/dL or; Obesity (BMI = 30 kg/m²) regardless of the presence of other components of the Metabolic Syndrome.
Exclusion criteria
Exclusion criteria: Pregnant, lactating or menopausal women; Athletes; Smokers; Vegans; Shift workers; With a history of HIV, digestive, hepatic, renal, cardiovascular, thyroid, cancer, inflammatory diseases or eating disorders; Who have a history of drug and/or alcohol abuse; Aversion or allergy to nuts; Who has had an infection in the last month; Consume more than 30 g/day of nuts; Make use of certain medications such as anti-inflammatory drugs, corticoids and antibiotics; Have problems that can interfere with chewing; Weight instability (5% of usual weight) in the last 3 months; Alcohol consumption > 21 units (˜168g) per week; Consumption of vitamin, mineral and omega 3 supplements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1- It is expected to find weight loss, which will be evaluated using the DEXA technique (Dual-energy X-ray Absortiometry) with fan-beam technology (Lunar Prodigy Advance 16 DXA System, version 13.31, GE Lunar ) at the beginning and end of the intervention, following the protocol recommended by the manufacturer, a weight loss of at least 4 kg is expected. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome 1 - It is expected to find a reduction in blood pressure in patients who have alterations initialy, a reduction in inflammatory biomarkers and oxidative stress, as well as verifying aspects related to the gene expression of these markers.;Secondary outcome 2 - It is expected to find a positive modulation of the intestinal microbiota with improvement in dysbiosis and a reduction in intestinal permeability.;Secondary outcome 3 - It is expected to find relationships between cashew nut intake and its oil and neuroendocrine markers of satiety.;Secondary outcome 4 - It is expected to find possible influences of genetic polymorphisms and responses to treatments with the cashew nut and its oil. | — |
Countries
Brazil
Contacts
Public ContactTalitha Silva Meneguelli
Universidade Federal de Viçosa
Outcome results
None listed